The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Evaluating real-world efficacy of durvalumab and tremelimumab in HCC
David Pinato, MD, PhD, Imperial College London, London, UK, comments on findings from the DR-real study, which aims to assess the efficacy of durvalumab plus tremelimumab in patients with hepatocellular carcinoma (HCC) in the real-world setting. Compared to Phase III data, the combination was found to be equally as safe and efficacious in the clinic. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
